Logo image of BCDA

BIOCARDIA INC (BCDA) Stock Price, Quote, News and Overview

NASDAQ:BCDA - Nasdaq - US09060U6064 - Common Stock - Currency: USD

2.85  0 (0%)

After market: 2.85 0 (0%)

BCDA Quote, Performance and Key Statistics

BIOCARDIA INC

NASDAQ:BCDA (5/9/2025, 8:00:01 PM)

After market: 2.85 0 (0%)

2.85

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High6.15
52 Week Low1.63
Market Cap13.34M
Shares4.68M
Float3.55M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-11 2025-08-11
IPO11-13 1996-11-13


BCDA short term performance overview.The bars show the price performance of BCDA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40

BCDA long term performance overview.The bars show the price performance of BCDA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BCDA is 2.85 USD. In the past month the price increased by 47.67%. In the past year, price decreased by -52.01%.

BIOCARDIA INC / BCDA Daily stock chart

BCDA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.97 326.55B
AMGN AMGEN INC 12.81 142.94B
GILD GILEAD SCIENCES INC 12.52 120.65B
VRTX VERTEX PHARMACEUTICALS INC N/A 109.26B
REGN REGENERON PHARMACEUTICALS 11.91 56.98B
ARGX ARGENX SE - ADR 93.64 33.56B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.67B
ONC BEIGENE LTD-ADR 5.79 25.01B
BNTX BIONTECH SE-ADR N/A 22.30B
NTRA NATERA INC N/A 20.66B
SMMT SUMMIT THERAPEUTICS INC N/A 17.79B
BIIB BIOGEN INC 7.47 17.32B

About BCDA

Company Profile

BCDA logo image BioCardia, Inc. is a clinical-stage biotherapeutic company. The company is headquartered in Sunnyvale, California and currently employs 17 full-time employees. The company is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Company Info

BIOCARDIA INC

320 Soquel Way

Sunnyvale CALIFORNIA 94070 US

CEO: Peter Altman

Employees: 19

BCDA Company Website

BCDA Investor Relations

Phone: 16502260123

BIOCARDIA INC / BCDA FAQ

What is the stock price of BIOCARDIA INC today?

The current stock price of BCDA is 2.85 USD.


What is the ticker symbol for BIOCARDIA INC stock?

The exchange symbol of BIOCARDIA INC is BCDA and it is listed on the Nasdaq exchange.


On which exchange is BCDA stock listed?

BCDA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BIOCARDIA INC stock?

8 analysts have analysed BCDA and the average price target is 15.81 USD. This implies a price increase of 454.74% is expected in the next year compared to the current price of 2.85. Check the BIOCARDIA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIOCARDIA INC worth?

BIOCARDIA INC (BCDA) has a market capitalization of 13.34M USD. This makes BCDA a Nano Cap stock.


How many employees does BIOCARDIA INC have?

BIOCARDIA INC (BCDA) currently has 19 employees.


What are the support and resistance levels for BIOCARDIA INC (BCDA) stock?

BIOCARDIA INC (BCDA) has a support level at 2.62 and a resistance level at 2.86. Check the full technical report for a detailed analysis of BCDA support and resistance levels.


Is BIOCARDIA INC (BCDA) expected to grow?

The Revenue of BIOCARDIA INC (BCDA) is expected to decline by -84.28% in the next year. Check the estimates tab for more information on the BCDA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIOCARDIA INC (BCDA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIOCARDIA INC (BCDA) stock pay dividends?

BCDA does not pay a dividend.


When does BIOCARDIA INC (BCDA) report earnings?

BIOCARDIA INC (BCDA) will report earnings on 2025-08-11.


What is the Price/Earnings (PE) ratio of BIOCARDIA INC (BCDA)?

BIOCARDIA INC (BCDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.25).


What is the Short Interest ratio of BIOCARDIA INC (BCDA) stock?

The outstanding short interest for BIOCARDIA INC (BCDA) is 1.1% of its float. Check the ownership tab for more information on the BCDA short interest.


BCDA Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to BCDA. When comparing the yearly performance of all stocks, BCDA is a bad performer in the overall market: 75.19% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BCDA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to BCDA. While BCDA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BCDA Financial Highlights

Over the last trailing twelve months BCDA reported a non-GAAP Earnings per Share(EPS) of -8.25. The EPS increased by 17.91% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -213.37%
ROE -949.34%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%81.48%
Sales Q2Q%-100%
EPS 1Y (TTM)17.91%
Revenue 1Y (TTM)-87.74%

BCDA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to BCDA. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of 61.55% and a revenue growth -84.28% for BCDA


Ownership
Inst Owners2.72%
Ins Owners17.32%
Short Float %1.1%
Short Ratio0.57
Analysts
Analysts82.5
Price Target15.81 (454.74%)
EPS Next Y61.55%
Revenue Next Year-84.28%